Patents by Inventor Jung sil Ro

Jung sil Ro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Maker for diagnosing HER2 inhibitor resistant cancer, diagnostic kit comprising same, and method for diagnosing HER2 inhibitor resistant cancer
    Patent number: 10190170
    Abstract: The present invention relates to a composition for detecting a marker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker. More particularly, the present invention relates to a composition for detecting a maker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker, wherein the present invention allows presence and absence of resistance to an HER2 inhibitor, which is typically prescribed to an HER2-positive cancer patient, in an HER2-positive cancer patient to be determined in an easier manner with remarkably high reliability.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: January 29, 2019
    Assignee: NATIONAL CANCER CENTER
    Inventors: Hae Ryung Chang, Youme Gim, Hae Rim Jung, Seung Yoon Nam, Jung sil Ro, Yon Hui Kim
  • MAKER FOR DIAGNOSING HER2 INHIBITOR RESISTANT CANCER, DIAGNOSTIC KIT COMPRISING SAME, AND METHOD FOR DIAGNOSING HER2 INHIBITOR RESISTANT CANCER
    Publication number: 20150368722
    Abstract: The present invention relates to a composition for detecting a marker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker. More particularly, the present invention relates to a composition for detecting a maker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker, wherein the present invention allows presence and absence of resistance to an HER2 inhibitor, which is typically prescribed to an HER2-positive cancer patient, in an HER2-positive cancer patient to be determined in an easier manner with remarkably high reliability.
    Type: Application
    Filed: May 29, 2015
    Publication date: December 24, 2015
    Inventors: Hae Ryung Chang, Youme Gim, Hae Rim Jung, Seung Yoon Nam, Jung sil Ro, Yon Hui Kim